Clinical Trials Logo
  1. Home
  2. Relapsed Solid Tumors
  3. NCT06150365

Single Arm Clinical Study on the Safety and Efficacy of Personalized KSX01-TCRT in Patients With Advanced Solid Tumors

Refractory Solid Tumors Clinical Trial

Official title:
Single Arm Clinical Study on the Safety and Efficacy of Personalized KSX01-TCRT in Patients With Advanced Solid Tumors

Clinical Trial Summary

This trial is a single arm, open phase I clinical study to investigate the safety and efficacy of personalized KSX01-TCRT in patients with advanced solid tumors. This experiment is divided into two parts: the dose increasing stage (Part A) and the dose expanding stage (Part B). For those enrolled in the planned expansion phase, the dose should have passed the safety assessment during the dose escalation phase.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06150365
Study type Interventional
Source Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Contact clinical trials ksh
Phone 18994103369
Email ksh-clinicalt@tcrximmune.com
Status Recruiting
Phase Early Phase 1
Start date November 7, 2023
Completion date December 1, 2028
View Details
See also
  Status Clinical Trial Phase
Completed NCT00404508 - A Phase II Study of Epigenetic Therapy to Overcome Chemotherapy Resistance in Refractory Solid Tumors Phase 2
Completed NCT02450136 - Single-arm Study to Evaluate the Safety and Efficacy of Pazopanib, in Subjects With FGFR2 Amplification, FGFR2 Mutation Refractory Solid Tumors N/A
Completed NCT02596503 - A Study of Eribulin in Combination With Oral Irinotecan for Adolescent and Young Adult Patients With Relapsed or Refractory Solid Tumors Phase 1
Completed NCT00759928 - PK Trial of Sorafenib & Erlotinib in Patients With Refractory Solid Tumors Phase 1
Completed NCT01247168 - An Open-Label, Dose-Escalation Study of AZD2461 Phase 1
Completed NCT00665990 - Phase I Study of Bevacizumab and Sorafenib Combined With Low Dose Cyclophosphamide in Patients With Refractory Solid Tumors and Leukemia Phase 1
Completed NCT02691793 - Study to Evaluate the Safety and Efficacy of Sunitinib, in Subject With Refractory Solid Tumors Phase 4
Completed NCT02450149 - Single-arm Study to Evaluate the Safety and Efficacy of Sorafenib, in Subjects With BRAF Mutation Refractory Solid Tumors N/A
Completed NCT02691767 - Study to Evaluate the Safety and Efficacy of Pazopanib, in Subject With Refractory Solid Tumors N/A
Terminated NCT00664586 - A Phase 1 Continuous Intravenous Infusion Study of Terameprocol (EM-1421) in Subjects With Refractory Solid Tumors Phase 1
Recruiting NCT05811975 - KSX01-TCRT Injection Project in Solid Tumors Early Phase 1
Completed NCT03810742 - Nanoliposomal Irinotecan (Nal-IRI, ONIVYDE®) in Combination With TAS-102 (LONSURF®) in Refractory Solid Tumors Phase 1
Terminated NCT03096340 - Safety and Pharmacokinetic Study of IT-141 in Monotherapy in Patients With Advanced Cancer Phase 1
Completed NCT02450123 - Single-arm Study to Evaluate the Safety and Efficacy of Sunitinib, in Subjects With RET Fusion Positive or FGFR2 Amplification, Refractory Solid Tumors N/A
Completed NCT02383368 - A Dose Escalation and Expansion Study of ASP4132 to Subjects With Advanced Refractory Tumors and Lymphoma Phase 1
Completed NCT00394446 - Phase 1, Multiple Dose Study of MPC-6827 in Subjects With Refractory Solid Tumors Phase 1
Completed NCT03052205 - A Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors Phase 1
Completed NCT02482441 - A Phase 1a/b Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of OMP-131R10 Phase 1
Recruiting NCT03739827 - Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors
Recruiting NCT05150457 - Safety and Preliminary Efficacy of BNA035 in Patients With Advanced Solid Tumors Phase 1